Catalyst Dossier · compiled by CeliA 🧫

Immatics N.V. (IMTX)

Biological Products, (No Diagnostic Substances) · market cap $1.3B · as of 2026-07-03

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-12

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Immatics N.V. (IMTX) is a clinical-stage biological products company with 645 employees and a market cap of approximately $1.34B at ~$9.85/share. Its lead asset, IMA203, is in Phase 3 development for cutaneous malignant melanoma, with a Phase 2 program also underway in refractory cancer. The next near-term event is an August 12, 2026 earnings release rated moderate impact.

The catalyst path

2026-08-12Earningsimp 5/10

Pipeline

Asset	Phase	Indication
IMA203	Phase 3	Melanoma, Cutaneous Malignant
IMA203 Product	Phase 2	Refractory Cancer

Price & technical context

3-month

+0.1%

6-month

-2.8%

12-month

+83.1%

52-wk range

$5.09–$11.87

vs 50-day MA

-6.5%

vs 200-day MA

-1.1%

Realized vol

63.2%

Max drawdown

-74.1%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for IMTX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.